Related references
Note: Only part of the references are listed.Can ACEIs and ARBs be safely continued in COVID-19:- The Evidence is here at Last!
Uma Velupandian
HEART VIEWS (2021)
Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention
Zunyou Wu et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Clinical Characteristics of Coronavirus Disease 2019 in China
W. Guan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Association of Renin-angiotensin-aldosterone System Inhibitors With Coronavirus Disease 2019 (COVID-19)-Related Outcomes in Korea: A Nationwide Population-based Cohort Study
Sun-Young Jung et al.
CLINICAL INFECTIOUS DISEASES (2020)
Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China
Juyi Li et al.
JAMA CARDIOLOGY (2020)
Angiotensin Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use Among Outpatients Diagnosed With COVID-19
David J. Bae et al.
AMERICAN JOURNAL OF CARDIOLOGY (2020)
Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are not associated with severeCOVID-19infection in a multi-siteUKacute hospital trust
Daniel M. Bean et al.
EUROPEAN JOURNAL OF HEART FAILURE (2020)
Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality
Emil L. Fosbol et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Use of inhibitors of the renin-angiotensin system in hypertensive patients and COVID-19 severity: A systematic review and meta-analysis
Jessica Barochiner et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2020)
Continued In-Hospital Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use in Hypertensive COVID-19 Patients Is Associated With Positive Clinical Outcome
Katherine W. Lam et al.
JOURNAL OF INFECTIOUS DISEASES (2020)
ACEI/ARB use and risk of infection or severity or mortality of COVID-19: A systematic review and meta-analysis
Xue Zhang et al.
PHARMACOLOGICAL RESEARCH (2020)
Effect of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with COVID-19: a Systematic Review and Meta-analysis of 28,872 Patients
Ranu Baral et al.
CURRENT ATHEROSCLEROSIS REPORTS (2020)
Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Death in Patients Hospitalised with COVID-19: A Retrospective Italian Cohort Study of 43,000 Patients
Gianluca Trifiro et al.
DRUG SAFETY (2020)
Predictors of severe or lethal COVID-19, including Angiotensin Converting Enzyme inhibitors and Angiotensin II Receptor Blockers, in a sample of infected Italian citizens
Francesca Bravi et al.
PLOS ONE (2020)
Prevalence and control rates of hypertension in the USA: 2017-2018
Muchi Ditah Chobufo et al.
INTERNATIONAL JOURNAL CARDIOLOGY HYPERTENSION (2020)
ACE2 localizes to the respiratory cilia and is not increased by ACE inhibitors or ARBs
Ivan T. Lee et al.
NATURE COMMUNICATIONS (2020)
Angiotensin-converting enzyme 2 and angiotensin 1-7: novel therapeutic targets
Fan Jiang et al.
NATURE REVIEWS CARDIOLOGY (2014)
A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury
K Kuba et al.
NATURE MEDICINE (2005)
Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2
CM Ferrario et al.
CIRCULATION (2005)
Share Paper
